Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

NCT04301843 is registered in ClinicalTrials.gov with Giselle Sholler as lead sponsor.

NCT NCT04301843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04301843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Lead sponsor
Giselle Sholler
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 25, 2020
Completion date
October 1, 2033
Enrollment
131 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma